AbbVie is looking like a steady option for a long-term hold, especially for the dividend. They currently have a 3.4% yield and have bumped payouts by over 330% since 2013, now sitting at $6.92 per share annually. People were worried about their main drug Humira losing its US patent in 2023, but their newer drugs Skyrizi and Rinvoq are picking up the slack. Skyrizi revenue grew 30.9% year over year in Q1, and Rinvoq was up 23.3%. They also have about 90 treatments in the pipeline, with roughly 60 in mid or late-stage development. Valuation seems reasonable too. Their forward P/E is 14, just slightly above their 5-year average of 13, and overall Q1 revenue grew 12.4%.